Technical Analysis for AEZS - AEterna Zentaris Inc.

Grade Last Price % Change Price Change
grade C 2.23 3.24% 0.07
AEZS closed up 3.24 percent on Friday, December 8, 2017, on 1.19 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical AEZS trend table...

Date Alert Name Type % Chg
Dec 8 Upper Bollinger Band Walk Other 0.00%
Dec 8 Outside Day Range Expansion 0.00%
Dec 8 Wide Bands Range Expansion 0.00%
Dec 8 Above Upper BB Strength 0.00%
Dec 8 Overbought Stochastic Strength 0.00%
Dec 8 Upper Bollinger Band Touch Strength 0.00%
Dec 7 Shooting Star Candlestick Bearish 3.24%
Dec 7 Wide Bands Range Expansion 3.24%
Dec 7 Overbought Stochastic Strength 3.24%
Dec 7 Upper Bollinger Band Touch Strength 3.24%

Older signals for AEZS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Aeterna Zentaris Inc. a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for oncology and endocrine therapy primarily in Switzerland, the United States, and Japan. It markets Cetrotide, a luteinizing hormone-releasing hormone antagonist treatment for in vitro fertilization. The company's product pipeline includes AEZS-108, which is in Phase III clinical trial for the treatment of endometrial cancer, as well as in Phase II clinical trial to treat triple-negative breast, ovarian, castration and taxane resistant prostate, and refractory bladder cancers; and AEZS-130, an oral diagnostic test that has completed Phase III clinical trial for adult growth hormone deficiency, as well as in Phase IIA clinical trial for the treatment of cancer-induced cachexia. Its product pipeline also comprise Ozarelix, which is in Phase II clinical trial for the treatment of prostate cancer; Perifosine that is in Phase I/II clinical trials for the treatment of neuroblastoma, glioma, and pediatric solid tumors; and AEZS-112 an oral anticancer agent, which has completed Phase I clinical trial for the treatment of solid tumors and lymphoma. In addition, the company's products in preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate for the treatment of prostate cancer; AEZS-129, 134, and 136 PI3K/Erk inhibitors for oncology; and AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.
Is AEZS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.25
52 Week Low 0.7816
Average Volume 397,275
200-Day Moving Average 1.9486
50-Day Moving Average 2.032
20-Day Moving Average 2.0585
10-Day Moving Average 2.101
Average True Range 0.12
ADX 20.04
+DI 22.02
-DI 11.31
Chandelier Exit (Long, 3 ATRs ) 1.9
Chandelier Exit (Short, 3 ATRs ) 2.21
Upper Bollinger Band 2.2294
Lower Bollinger Band 1.8876
Percent B (%b) 1.0
BandWidth 16.604324
MACD Line 0.0476
MACD Signal Line 0.0287
MACD Histogram 0.0188
Fundamentals Value
Market Cap 35.93 Million
Num Shares 16.1 Million
EPS -1.71
Price-to-Earnings (P/E) Ratio -1.30
Price-to-Sales 28.12
Price-to-Book 6.12
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.46
Resistance 3 (R3) 2.44 2.35 2.42
Resistance 2 (R2) 2.35 2.29 2.36 2.40
Resistance 1 (R1) 2.29 2.26 2.32 2.31 2.39
Pivot Point 2.20 2.20 2.22 2.21 2.20
Support 1 (S1) 2.14 2.14 2.17 2.16 2.07
Support 2 (S2) 2.05 2.11 2.06 2.06
Support 3 (S3) 1.99 2.05 2.04
Support 4 (S4) 2.01